Category: MedtronicSyndicate content

Progress on clinical trials and demographic information | Regulatory news for the week of February 23, 2015

February 24, 2015 by MassDevice

Here's a look at some of the top regulatory stories for medical device companies this week: Recent progress on demographic information and clinical trials; Moving toward a national medical device postmarket surveillance system; Medtronic wins CE Mark for Euphora Semicompliant balloon catheter; Simplify Medical wins CE Mark for MRI-safe cervical disc

Recent progress on demographic information and clinical trials

February 19, 2015 by MassDevice

Barbara D. Buch, M.D.

Overactive bladder treatment: Advanced Uro-solutions bought by Medtronic

February 24, 2015 by Mark Hollmer

Medtronic has snatched up Advanced Uro-solutions, a Tennessee company with an FDA-cleared neurostimulation device to treat overactive bladder.

Overactive bladder treatment: Advanced Uro-solutions bought by Medtronic

Medtronic (NYSE:MDT) has wrapped up yet another acquisition, buying Advanced Uro-Solutions, a Tennessee company whose neurostimulation products focus on treating patients with overactive bladder, for an undisclosed amount of money.

Epilepsy: Medtronic touts 5 year results on SANTE trial

February 23, 2015 by Mark Hollmer

Medtronic’s DBS therapy for treatment-resistant epilepsy has produced long-lasting improvements in quality of life after 5 years, according to detailed results from a pivotal clinical trial.

Medtronic CFO Ellis: Covidien deal frees up 25% more cash

Medicare ups reimbursement for Medtronic PAD device

February 22, 2015 by Val Kennedy

Medicare plans to provide supplemental reimbursement to hospitals for patients treated on an outpatient basis with Medtronic's new In.Pact Admiral drug-coated balloon for peripheral artery disease (PAD) in the upper leg.

Medtronic CFO Ellis: Covidien deal frees up 25% more cash

Renal Denervation: Medtronic taking another shot at drug-resistant hypertension

February 20, 2015 by Mark Hollmer

Medtronic is taking another shot at renal denervation to treat drug-resistant hypertension, a year after a pivotal trial for its key product in the space failed to meet its efficacy endpoint.

Renal denervation: Analysis highlights 'confounding' factors in Medtronic's Symplicity-3 trial

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

AHA, Medtronic team up to reduce recurrent strokes

February 18, 2015 by Mark Hollmer

Medtronic will work with the American Heart Association/American Stroke Association to reduce repeat strokes for which a cause isn’t known.

Medtronic's expanding services biz tops $1B in sales

Medtronic (NYSE:MDT) and the American Heart Association/American Stroke Association will ally on a project focused on reducing repeat strokes for which a cause isn’t known.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Medtronic's managed services biz books $1B in sales

February 18, 2015 by Brian Johnson

Medtronic CEO Omar Ishrak tells analysts the company's managed services business for cath labs is expanding into new markets, with booked sales topping the $1 billion mark through its fiscal 3rd quarter.

Medtronic's expanding services biz tops $1B in sales

Get the complete picture with a MassDevice Plus membership. Registered users can login here.